Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations.

Area of Science:

• Pharmacokinetics and Drug Development
• Bioequivalence Study Design
• Pharmacometric Modeling

Background:

• Model-based bioequivalence (MBBE) utilizes nonlinear mixed-effect models for pharmacokinetic endpoint estimation.
• MBBE serves as an alternative to non-compartmental analysis (NCA) in bioequivalence studies with limited sampling.
• Assessing relative bioavailability between multi-source drug products is crucial for generic drug approval.

Purpose of the Study:

• To evaluate MBBE against traditional methods for assessing relative bioavailability of different valproic acid formulations.
• To predict the multiple-dose performance of an extended-release formulation using single-dose data.
• To compare the discriminatory power of MBBE and NCA in bioequivalence studies.

Main Methods:

• MBBE analysis was applied to estimate bioequivalence endpoints (T/R GMR for AUC and Cmax).
• Data from a single-dose, 2-period, 2-sequence bioequivalence study in 14 subjects were used.
• A locally developed valproic acid extended-release formulation (Test) was compared to a brand-name delayed-release formulation (Reference).

Main Results:

• MBBE analysis showed higher discrimination for Cmax compared to standard NCA, overcoming sampling design limitations.
• Simulation-based studies predicted bioequivalence for total and unbound valproic acid in a multiple-dose scenario.
• The impact of saturable valproic acid binding on bioequivalence conclusions was considered.

Conclusions:

• MBBE analysis proved superior to NCA in identifying product differences and addressing experimental design limitations.
• Extended-release properties of the test formulation are predicted to maintain steady-state performance with reduced peak-to-trough fluctuations.
• The findings suggest MBBE can reduce the need for further experimentation in healthy subjects.